HighPoint Advisor Group LLC Buys Shares of 17,818 Gilead Sciences, Inc. (NASDAQ:GILD)

HighPoint Advisor Group LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, Holdings Channel.com reports. The fund bought 17,818 shares of the biopharmaceutical company’s stock, valued at approximately $1,443,000.

Several other hedge funds have also recently added to or reduced their stakes in GILD. Tompkins Financial Corp increased its holdings in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares in the last quarter. Fortitude Family Office LLC purchased a new position in Gilead Sciences during the 4th quarter valued at about $29,000. Private Wealth Management Group LLC purchased a new position in Gilead Sciences during the 4th quarter valued at about $29,000. Sachetta LLC purchased a new position in Gilead Sciences during the 4th quarter valued at about $30,000. Finally, Rakuten Securities Inc. purchased a new position in Gilead Sciences during the 4th quarter valued at about $33,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Down 1.7 %

Shares of GILD stock opened at $63.15 on Wednesday. The stock has a market cap of $78.68 billion, a price-to-earnings ratio of 175.42, a price-to-earnings-growth ratio of 1.28 and a beta of 0.20. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The firm’s 50 day moving average price is $65.79 and its two-hundred day moving average price is $73.13.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. Gilead Sciences’s revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.37 earnings per share. On average, analysts anticipate that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.88%. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Wall Street Analyst Weigh In

GILD has been the subject of a number of recent research reports. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a report on Wednesday, April 24th. Barclays lowered their price target on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a report on Monday, April 29th. Wells Fargo & Company lowered their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. Finally, UBS Group lowered their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.